IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $35.00 | Outperform | Oppenheimer |
SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D
424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)
8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
10-Q - OnKure Therapeutics, Inc. (0001637715) (Filer)
424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)
EFFECT - OnKure Therapeutics, Inc. (0001637715) (Filer)
S-1 - OnKure Therapeutics, Inc. (0001637715) (Filer)
D - OnKure Therapeutics, Inc. (0001637715) (Filer)
3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
BOULDER, Colo., Nov. 05, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure Therapeutics, will present a corporate overview at the Stifel Healthcare Conference, on November 18, 2024 at 1:50 p.m. ET in New York, NY. Stifel Healthcare ConferenceDate: Monday, November 18, 2024Time: 1:50 p.m. ETFormat: Corporate PresentationWebcast: Link A live webcast of the event can be accessed under "Events" on the Investor's section of the Company's website at www.onkure.com. A
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D
Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00